Research article · 15 Apr 2026
Conference abstractPublished 9 May 2016
Human GRK4γ142V variant promotes AT1R-mediated hypertension via renal HDAC1 inhibition and predicts the blood pressure response to angiotensin receptor blockade
The George Washington University School of Medicine & Health Sciences, USA
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
The influence of a single gene on the etiology of essential hypertension may be difficult to ascertain, unless the gene interacts with other genes that are germane to blood pressure (BP) regulation. G protein-coupled receptor kinase type 4 (GRK4) is one such gene. Nonsynonymous GRK4 variants, R65L, A142V and A486V are associated with essential hypertension. The dopamine D1 receptor (D1R) and angiotensin II type-I receptor (AT1R) reciprocally regulate renal sodium excretion and BP. hGRK4Ã?³142V transgenic mice have high blood pressure (BP) due to the impairment of the natriuretic function of D1R and increased expression and activity of the AT1R, that counteract the renal physiological effects of the D1R. hGRK4Ã?³142V phosphorylates histone deacetylase type-1 (HDAC1) but not HDAC2 and promotes HDAC1 export from the nucleus to the cytoplasm, resulting in increased AT1R expression. There is specificity of these effects because GRK4WT, but not GRK2WT, decreases AT1R expression. Moreover, AT1R blockade and the deletion of the Agtr1a gene normalize the hypertension in hGRK4Ã?³142V mice. The studies in mice can be translated to humans. In 829 patients with essential hypertension we found that carriers of hGRK4Ã?³142V had a greater decrease in systolic BP in response to angiotensin receptor blockers (ARBs) than non-carrier hypertensive patients. By contrast, those with variants only at hGRK4Ã?³486V were less likely to achieve the BP goal in response to an ARB than those with no variants. These findings illustrate the unique role of GRK4 by targeting receptors with opposite physiological activity for the same goal of maintaining BP homeostasis and thus making the GRK4 a relevant therapeutic target to control BP.
Subjects
Nephrology & UrologyAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in Journal of Nephrology & Therapeutics.
Brief report · 30 Mar 2026
Renal Fibrosis: Targeting Pathways For New Therapies
Brief report · 30 Mar 2026
SGLT2 Inhibitors: A New Era for Diabetic Kidney Disease
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Nephrology & Therapeutics
- SubjectNephrology & Urology
- BylineArticles whose byline prints “Pedro A Jose”
